血脂异常患者ApoE和SLCO1B1基因多态性与阿托伐他汀调脂治疗后血脂和肝功能的相关性
Correlation between ApoE and SLCO1B1 gene polymorphisms and blood lipids and liver function of patients with dyslipidemia after atorvastatin lipid-lowering therapy
许娇娇 1尹忠鹏 1王淑梅 1张晨涛 1王一鑫 1王娜1
作者信息
- 1. 沧州市人民医院 药学部,河北 沧州 061000
- 折叠
摘要
目的 研究血脂异常患者载脂蛋白(ApoE)、有机阴离子转运蛋白家族成员 1B1(SLCO1B1)基因多态性与阿托伐他汀调脂治疗后血脂、肝功能的相关性.方法 选取 2020 年 1 月—2023 年9 月就诊于沧州市人民医院的 128 例高脂血症患者,阿托伐他汀治疗至少 4 周,检测ApoE、SLCO1B1基因和血脂、肝功能指标,分析其因型与调脂疗效、肝功能指标关系.结果 阿托伐他汀治疗后,ApoE基因表型E2 组三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)水平均较治疗前改善,E3组总胆固醇(TC)、HDL-C、低密度脂蛋白胆固醇(LDL-C)水平均较治疗前改善,E4 组HDL-C水平均较治疗前改善,差异有统计学意义(P＜0.05).治疗后,ApoE基因表型各组丙氨酸转氨酶(ALT)差异无统计学意义,仅E3 组谷氨酰转移酶(GGT)差异有统计学意义(P＜0.05).阿托伐他汀治疗后,SLCO1B1基因表型Ⅰ型的TC、TG、HDL-C、LDL-C均较治疗前改善,Ⅱ型HDL-C较治疗前改善,差异有统计学意义(P＜0.05).治疗后,SLCO1B1基因表型各组ALT、GGT差异无统计学意义.结论 临床使用阿托伐他汀时,可检测ApoE、SLCO1B1基因多态性评估降脂疗效,实现阿托伐他汀个体化用药.
Abstract
Objective To investigate the association of ApoE and SLCO1B1 polymorphism with lipid and liver function in patients with dyslipidemia after lipid-lowering with atorvastatin.Methods A total of 128 patients with dyslipidemia in Cangzhou People's Hospital from January 2020 to September 2023 were collected.The patient received at least 4 weeks of atorvastatin therapy.ApoE genes,SLCO1B1 genes,blood lipids,and liver function indicators were detected.The relationship between their genotype and lipid-lowering efficacy,as well as liver function indicators was evaluate.Results After atorvastatin treatment,the levels of TG and HDL-C of ApoE gene phenotype in E2 group,the levels of TC,HDL-C,LDL-C,and LDL-C in E3 group,and the levels of HDL-C in E4 group were improved compared with before treatment,and the difference was statistically significant(P＜0.05).After treatment,there was no statistically significant difference in ALT among ApoE gene phenotype groups,while only the difference in GGT of E3 group was statistically significant(P＜0.05).After atorvastatin therapy,TC,TG,HDL-C,and LDL-C of SLCO1B1 gene phenotype Ⅰ improved compared to before treatment,while HDL-C of SLCO1B1 gene phenotype Ⅱ improved compared to before treatment,with statistical significance(P＜0.05).After treatment,there was no statistically significant difference in ALT and GGT among the SLCO1B1 gene phenotype groups.Conclusion In the clinical application of statins,the lipid-lowering efficacy can be evaluated by detecting APOE and SLCO1B1 gene polymorphisms,and the individualized use of atorvastatin can be realized.
关键词
阿托伐他汀/血脂异常/ApoE基因/SLCO1B1基因/血脂/肝功能Key words
atorvastatin/dyslipidemia/ApoE gene/SLCO1B1 gene/blood lipid/liver function引用本文复制引用
基金项目
河北省医学科学研究课题(20220310)
出版年
2024
NETL
NSTL
万方数据